Inhaled Corticosteroids Safe for Asthma in Early Pregnancy

Women with asthma who continued using inhaled corticosteroids (ICS) during the first trimester of pregnancy did not experience higher rates of adverse outcomes compared to those who stopped the medication, according to a nationwide cohort study conducted in South Korea. The research, published in the journal Allergy, aimed to address concerns regarding the safety of ICS use during early gestation, a critical period for fetal development. The study analyzed data from the South Korean National Health Insurance Service database, encompassing a large population of pregnant women diagnosed with asthma. Researchers identified 10,973 pregnant women with asthma who continued ICS use in the first trimester and compared them to 10,973 matched controls who discontinued ICS use during the same period. The primary outcomes assessed included major congenital anomalies, spontaneous abortion, preterm birth, low birth weight, and small for gestational age infants. The findings indicated no statistically significant differences in the incidence of these adverse pregnancy outcomes between the two groups. Specifically, the rate of major congenital anomalies was 3.4% in the ICS continuation group versus 3.3% in the discontinuation group. Spontaneous abortion rates were 1.4% and 1.3%, respectively. Preterm birth occurred in 7.7% of the continuation group and 7.8% of the discontinuation group, while low birth weight was observed in 6.5% and 6.7%, and small for gestational age infants in 7.2% and 7.4%. These results provide reassurance to clinicians and patients that continuing ICS therapy for asthma management during the first trimester of pregnancy is unlikely to increase the risk of adverse fetal or neonatal outcomes. Asthma management during pregnancy is crucial, as uncontrolled asthma can pose significant risks to both the mother and the fetus, including preeclampsia, intrauterine growth restriction, and preterm birth. Inhaled corticosteroids are the cornerstone of long-term asthma control, effectively reducing airway inflammation and preventing exacerbations. Previous studies on the safety of ICS during pregnancy have yielded mixed results, contributing to uncertainty among healthcare providers and pregnant individuals. This large-scale, nationwide study from South Korea, with its robust methodology and comprehensive data, offers strong evidence supporting the continued use of ICS in early pregnancy when clinically indicated. The study's authors emphasized that the benefits of maintaining maternal asthma control likely outweigh any potential, and in this study, unobserved, risks associated with ICS exposure in the first trimester. They recommend that pregnant women with asthma should continue their ICS therapy as prescribed by their healthcare provider and discuss any concerns regarding medication safety during pregnancy. The study's findings are particularly important given the increasing prevalence of asthma and the growing number of women who are pregnant or planning pregnancy while managing chronic respiratory conditions. The research contributes to a growing body of evidence supporting the safe use of essential medications during pregnancy, enabling better maternal and fetal health outcomes.